Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

SAINT-PREX, Switzerland -- Ferring today published its 2023 Annual Report showing the company’s annual revenues were €2.2 billion, a decrease of -4% on the previous year at actual exchange rates (AER), but an increase of +1% at constant exchange rates (CER). EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million. Read More

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring
Ads Links by Easy Branches
Play online games for free at games.easybranches.com
Guest Post Services www.easybranches.com/contribute
Sunak May Struggle to Turn Key Inflation Victory Into Votes